

Pertti Jaakko Neuvonen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8919721/pertti-jaakko-neuvonen-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

334
papers

20,512
citations

76
h-index

124
g-index

337
ext. papers

22,291
ext. citations

4.3
avg, IF

6.69
L-index

#	Paper	IF	Citations
334	Lifetime antimicrobial use is associated with weight status in early adolescence-A register-based cohort study. <i>Pediatric Obesity</i> , 2021 , 16, e12727	4.6	1
333	Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. <i>Clinical and Translational Science</i> , 2020 , 13, 345-351	4.9	10
332	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 781-808	6.2	17
331	Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition. <i>Microbiome</i> , 2020 , 8, 121	16.6	7
330	Sotalol, unlike the other beta-blockers, increases the QT interval and risk of torsades de pointes ventricular tachycardia in severe poisonings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 125, 487-488	3.1	
329	CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 448-457	6.1	11
328	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 377-385	4	9
327	Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 124, 330-340	3.1	13
326	Response to "Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?". <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 322	6.1	0
325	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 219-228	6.1	34
324	Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 653-662	6.1	11
323	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 122, 341-345	3.1	8
322	Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study. <i>BMC Geriatrics</i> , 2018 , 18, 142	4.1	3
321	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 495-504	6.1	11
320	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 141-150	4	16
319	Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 687-697	4.5	12
318	Voriconazole greatly increases the exposure to oral buprenorphine. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1615-1622	2.8	9

317	Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 1378-1385	2.7	15
316	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 83-95	5.5	21
315	Postoperative oxycodone in breast cancer surgery: What factors associate with analgesic plasma concentrations?. <i>Scandinavian Journal of Pain</i> , 2016 , 12, 118-119	1.9	
314	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1363-1371	2.8	12
313	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. <i>Pharmacological Reviews</i> , 2016 , 68, 168-241	22.5	128
312	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 1364-71	4	23
311	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2016 , 4, e00271	3.1	8
310	High-Dose Methylprednisolone Has No Benefit Over Moderate Dose for the Correction of Tetralogy of Fallot. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 870-876	2.7	12
309	Lipid Rescue - Efficacy and Safety Still Unproven. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 119, 345-8	3.1	6
308	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 321-7	2.8	24
307	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 97, 650-8 ^{6.1}		57
306	The role of concentration--effect relationships in the QTc interval prolongation: case sotalol. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 1040-1	3.8	1
305	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1655-60	4	20
304	Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1131-8	3.8	24
303	Drug-Related Inadvertent Deaths in a University Hospital--A Declining Trend. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015 , 117, 421-6	3.1	18
302	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 382-7	1.9	25
301	Effect of timing and route of methylprednisolone administration during pediatric cardiac surgical procedures. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 180-5	2.7	21
300	Effect of grapefruit juice on the bioactivation of prasugrel. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 139-45	3.8	11

299	Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 975-85	3.8	24
298	Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 319-29	2.8	25
297	Infections and possible vaccine-drug interactions. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 889-90	2.8	1
296	Grapefruit juice inhibits the metabolic activation of clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 307-13	6.1	43
295	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1202-9	4	51
294	Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 498-507	6.1	99
293	Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. <i>BMC Geriatrics</i> , 2014 , 14, 121	4.1	15
292	Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 2068-76	4	8
291	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1293-301	2.8	22
290	Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 867-75	2.8	12
289	Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. <i>In Silico Pharmacology</i> , 2013 , 1, 6	4.3	33
288	Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 50-9	4	46
287	Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. <i>Annals of Thoracic Surgery</i> , 2013 , 95, 2126-32	2.7	52
286	Intravenous lipid emulsion entraps amitriptyline into plasma and can lower its brain concentration--an experimental intoxication study in pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013 , 113, 193-200	3.1	34
285	A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 763-81	6.2	27
284	A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 472-8	1.7	39
283	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1488-96	3.8	28
282	SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 19-24	1.9	29

281	No antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptyline. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 110, 378-83	3.1	25
280	Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 111, 182-8	3.1	18
279	Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 111, 325-32	3.1	27
278	The analgesic concentration of oxycodone with co-administration of paracetamol -- a dose-finding study in adult patients undergoing laparoscopic cholecystectomy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 111, 391-5	3.1	21
277	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. <i>Trends in Pharmacological Sciences</i> , 2012 , 33, 312-22	13.2	73
276	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. <i>British Journal of Pharmacology</i> , 2012 , 165, 2787-98	8.6	59
275	St John's wort greatly decreases the plasma concentrations of oral S-ketamine. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 743-50	3.1	20
274	Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 68-71	6.1	55
273	Increased incidence of Merkel cell carcinoma among younger statin users. <i>Cancer Epidemiology</i> , 2012 , 36, 421-4	2.8	19
272	In vitro and in vivo entrapment of bupivacaine by lipid dispersions. <i>Journal of Chromatography A</i> , 2012 , 1254, 125-31	4.5	7
271	Statins and hip fracture prevention--a population based cohort study in women. <i>PLoS ONE</i> , 2012 , 7, e48095	3.7	28
270	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 681-8	2.8	10
269	S-ketamine concentrations are greatly increased by grapefruit juice. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 979-86	2.8	18
268	Re: Pergolizzi et al. 2011: Exposure to potential CYP450 pharmacokinetic drug-drug interactions. <i>Pain Practice</i> , 2012 , 12, 81-2	3	1
267	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 257-67	3.8	28
266	Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 110, 245-52	3.1	27
265	Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 110, 207-18	3.1	7
264	Acetaminophen improves analgesia but does not reduce opioid requirement after major spine surgery in children and adolescents. <i>Spine</i> , 2012 , 37, E1225-31	3.3	63

263	Intravenous lipid emulsion only minimally influences bupivacaine and mepivacaine distribution in plasma and does not enhance recovery from intoxication in pigs. <i>Anesthesia and Analgesia</i> , 2012 , 114, 901-6	3.9	20
262	Pharmacokinetics of intravenous paracetamol in elderly patients. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 121-9	6.2	53
261	Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. <i>Clinical Drug Investigation</i> , 2011 , 31, 143-53	3.2	33
260	Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. <i>Drugs and Aging</i> , 2011 , 28, 41-50	4.7	34
259	Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 359-67	2.9	47
258	Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 302-8	1.7	28
257	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 718-26	3.8	72
256	Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 579-86	6.1	44
255	The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 151-5	2.8	12
254	Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 863-4	2.8	9
253	No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 1159-67	2.8	6
252	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. <i>Pharmacological Reviews</i> , 2011 , 63, 157-81	22.5	465
251	Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1977-86	4	54
250	Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. <i>Circulation</i> , 2011 , 124, 1138-50	16.7	58
249	Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 904-11	4	37
248	Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1063-7	5.9	23
247	SLCO1B1 polymorphism and oral antidiabetic drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 107, 775-81	3.1	30
246	Grapefruit juice enhances the exposure to oral oxycodone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 107, 782-8	3.1	39

245	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 78-87	3.8	54
244	Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 223-30	6.1	49
243	Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 101-8	2.9	26
242	Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 387-97	2.8	52
241	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 497-502	2.8	22
240	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 865-70	2.8	6
239	Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 977-85	2.8	46
238	High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 51-60	3.2	72
237	St John's wort greatly reduces the concentrations of oral oxycodone. <i>European Journal of Pain</i> , 2010 , 14, 854-9	3.7	45
236	Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. <i>Annals of Emergency Medicine</i> , 2010 , 56, 402-408.e2	2.1	61
235	Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. <i>European Journal of Pain</i> , 2010 , 14, 625-9	3.7	31
234	Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 323-32		60
233	Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. <i>Pharmacology Biochemistry and Behavior</i> , 2009 , 92, 283-90	3.9	10
232	Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 89-95	2.8	13
231	Voriconazole drastically increases exposure to oral oxycodone. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 263-71	2.8	62
230	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 207-13	3.8	48
229	Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. <i>Pharmacogenomics</i> , 2009 , 10, 1617-24	2.6	150
228	CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 2359-66	4	41

227	Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 447-57	1.9	50
226	Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. <i>Anesthesiology</i> , 2009 , 110, 1371-8	4.3	74
225	The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 403-11	6.1	73
224	Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 488-96	6.1	67
223	No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 78-86	3.8	47
222	Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 405-10	3.8	25
221	The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 818-25	3.8	59
220	Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 463-74	6.2	145
219	Long-term persistence with statin therapy: a nationwide register study in Finland. <i>Clinical Therapeutics</i> , 2008 , 30 Pt 2, 2228-40	3.5	60
218	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 311-21	2.9	76
217	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. <i>Pharmacogenomics Journal</i> , 2008 , 8, 268-77	3.5	52
216	Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 73-80	4	92
215	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 77-90	1.9	63
214	Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 921-6	1.9	28
213	Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 333-40	3.2	35
212	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 937-42	1.9	54
211	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 17-24	2.8	34
210	Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 25-30	2.8	66

209	Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 511-9	2.8	11
208	Global analysis of genetic variation in SLCO1B1. <i>Pharmacogenomics</i> , 2008 , 9, 19-33	2.6	143
207	Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 88, 187-191		
206	Effect of Caffeine-Containing versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 94, 13-18	3.1	8
205	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 103, 157-65	3.1	38
204	Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 833-9	6.1	71
203	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 116-20	3.8	20
202	Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 732-40	3.8	59
201	Effect of voriconazole on the pharmacokinetics of diclofenac. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21, 651-6	3.1	17
200	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 463-9	2.8	29
199	Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 829-36	2.8	12
198	Voriconazole and fluconazole increase the exposure to oral diazepam. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 941-9	2.8	39
197	Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease. <i>Anesthesiology</i> , 2007 , 106, 43-55	4.3	19
196	Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 217-23	2.8	31
195	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 409-15	2.8	103
194	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 451-61	2.8	55
193	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 463-72	2.8	68
192	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 503-9	2.8	28

191	The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 645-51	2.8	19
190	Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1967-72	5.9	36
189	Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 2091-6	4	33
188	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 801-8 ^{1.9}		85
187	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 873-9	1.9	366
186	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 79-85	3.1	89
185	Drug-related visits to a district hospital emergency room. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 212-7	3.1	26
184	Effect of rifampicin on the pharmacokinetics of atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 555-8	3.1	11
183	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 99, 44-51	3.1	112
182	Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 99, 168-72	3.1	11
181	Effect of rifampicin on the pharmacokinetics of pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 70-8	3.8	64
180	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 706-15	3.8	47
179	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 345-57	3.8	55
178	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 231-42	6.1	40
177	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 362-70	6.1	96
176	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 356-66	6.1	185
175	Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 502-8	6.1	22
174	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 565-81	6.1	579

173	Risks associated with selective serotonin reuptake inhibitors in pregnancy. <i>Obstetrics and Gynecology</i> , 2005 , 106, 1289-96	4.9	148
172	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 303-9	1.9	100
171	Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. <i>Anesthesiology</i> , 2005 , 103, 712-7	4.3	56
170	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 404-14	6.1	84
169	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 468-78	6.1	287
168	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 154-67	6.1	113
167	Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 400-11	6.1	73
166	Cyclosporine markedly raises the plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 388-99	6.1	163
165	Out-of-hospital administration of activated charcoal by emergency medical services. <i>Annals of Emergency Medicine</i> , 2005 , 45, 207-12	2.1	25
164	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 433-9	3.8	38
163	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 208-17	3.8	34
162	Effects of grapefruit juice on the absorption of levothyroxine. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 337-41	3.8	46
161	Effects of grapefruit juice on the pharmacokinetics of acebutolol. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 659-63	3.8	30
160	Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 97, 104-8	3.1	30
159	Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 97, 249-56	3.1	133
158	Effect of itraconazole on the pharmacokinetics of atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 97, 395-8	3.1	7
157	The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. <i>Anesthesia and Analgesia</i> , 2005 , 100, 1352-1356	3.9	27
156	Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 56-60	3.8	112

155	Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 390-6	3.8	32
154	Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004 , 95, 120-3		6
153	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 441-7	3.8	76
152	Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 349-53	3.8	76
151	Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 101-9	6.1	67
150	Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 184-90	6.1	78
149	Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 331-41	6.1	80
148	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 239-49	6.1	66
147	Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 598-606	6.1	107
146	Prescription of hazardous drugs during pregnancy. <i>Drug Safety</i> , 2004 , 27, 899-908	5.1	45
145	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 181-7	3.8	54
144	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 429-40		358
143	Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 192-8	6.1	111
142	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. <i>Diabetologia</i> , 2003 , 46, 347-51	10.3	231
141	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. <i>Diabetologia</i> , 2003 , 46, 1319-23	10.3	145
140	Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. <i>European Journal of Clinical Pharmacology</i> , 2003 , 58, 653-7	2.8	18
139	Prescription drugs during pregnancy and lactation—a Finnish register-based study. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 127-33	2.8	56
138	Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 538-44	6.1	146

137	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 25-31	6.1	17
136	Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 178-85	6.1	28
135	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 380-7	6.1	136
134	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 427-32	3.8	30
133	Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 819-50	6.1	473
132	Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 2002 , 57, 799-804	2.8	126
131	Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 137-41	2.8	51
130	Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 362-9	6.1	48
129	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 326-32	6.1	156
128	Gemfibrozil greatly increases plasma concentrations of cerivastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 685-91	6.1	255
127	Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1352-6	4	167
126	Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 43-9	4.7	18
125	Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 631-5	4	125
124	Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. <i>European Journal of Clinical Pharmacology</i> , 2001 , 57, 37-42	2.8	33
123	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 399-407	3.8	14
122	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 547-53	3.8	109
121	Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 344-350	6.1	20
120	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 484-492	6.1	

119	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 194-200	6.1	45
118	Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 340-5	6.1	140
117	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 400-6	6.1	80
116	The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 58-65	6.1	76
115	Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 255-60	6.1	21
114	Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2001 , 88, 187-91		17
113	The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. <i>Anesthesia and Analgesia</i> , 2000 , 91, 1207-12	3.9	7
112	Identification of drugs ingested in acute poisoning: correlation of patient history with drug analyses. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 749-52	3.2	42
111	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. <i>Anesthesia and Analgesia</i> , 2000 , 91, 1207-1212	3.9	17
110	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1-hydroxylation. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 333-7	3.8	56
109	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 591-5	3.8	34
108	The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000 , 107, 770-5	3.7	106
107	Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 215-21	6.1	28
106	Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 382-90	6.1	37
105	Plasma concentrations of active simvastatin acid are increased by gemfibrozil. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 122-9	6.1	197
104	Morphine clearance and effects in newborn infants in relation to gestational age. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 160-6	6.1	50
103	Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 384-90	6.1	116
102	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 487-94	6.1	74

101	Rifampin decreases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 495-500	6.1	70
100	Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 592-7	6.1	98
99	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 225-9	2.8	94
98	Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 411-5	2.8	73
97	Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. <i>Journal of Pediatrics</i> , 2000 , 136, 767-770	3.6	73
96	Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 85, 157-61		51
95	Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 84, 94-7		29
94	Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 84, 143-6		21
93	Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 84, 165-9		7
92	Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 85, 201-5		24
91	Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 85, 29-32		38
90	Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 448-53	6.1	51
89	Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 33-9	6.1	82
88	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 377-81	6.1	25
87	Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 118-27	6.1	141
86	Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 589-93	6.1	29
85	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 401-7	6.1	28
84	Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 317-21	3.2	5

83	Plasma Clearance of Fentanyl in Relation To Gestational Age and Birth Weight. <i>Pediatric Research</i> , 1999 , 45, 901-901	3.2	
82	Effect of itraconazole on the pharmacokinetics of atorvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 58-65	6.1	234
81	Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 397-402	6.1	218
80	Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 648-54	6.1	41
79	Grapefruit juice substantially increases plasma concentrations of buspirone. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 655-60	6.1	110
78	Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 363-8	6.1	84
77	Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 640-5	6.1	55
76	Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 477-83	6.1	248
75	Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 177-82	6.1	236
74	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 332-41	6.1	343
73	The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998 , 83, 135-8		28
72	The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. <i>European Journal of Clinical Pharmacology</i> , 1998 , 54, 53-8	2.8	214
71	A prospective study of acute poisonings in Finnish hospital patients. <i>Human and Experimental Toxicology</i> , 1998 , 17, 307-11	3.4	25
70	The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil. <i>Anesthesia and Analgesia</i> , 1998 , 87, 190-194	3.9	14
69	The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. <i>Anesthesia and Analgesia</i> , 1998 , 87, 190-4	3.9	38
68	Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 75-7	5.6	29
67	Pharmacokinetics of verapamil in overdose. <i>Human and Experimental Toxicology</i> , 1997 , 16, 35-7	3.4	19
66	Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil. <i>Journal of Toxicology: Clinical Toxicology</i> , 1997 , 35, 263-8		22

65	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 29-33	3.8	6
64	Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1997 , 81, 31-4		14
63	Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. <i>Canadian Journal of Anaesthesia</i> , 1997 , 44, 1269-74	3	4
62	Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 348-54	6.1	134
61	Itraconazole increases plasma concentrations of quinidine. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 510-7	6.1	77
60	Rifampin reduces plasma concentrations and effects of zolpidem. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 629-34	6.1	59
59	Triazolam is ineffective in patients taking rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 8-14	6.1	90
58	Itraconazole greatly increases plasma concentrations and effects of felodipine. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 410-5	6.1	117
57	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 29-33	3.8	20
56	Effect of activated charcoal on the pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 46-50	3.2	10
55	Itraconazole decreases renal clearance of digoxin. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 609-13	3.2	147
54	The effect of pH on the in-vitro dissolution of three second-generation sulphonylurea preparations: mechanism of antacid-sulphonylurea interaction. <i>Journal of Pharmacy and Pharmacology</i> , 1996 , 48, 899-908		6
53	Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. <i>Anesthesiology</i> , 1996 , 85, 1246-52	4.3	55
52	The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. <i>Anesthesia and Analgesia</i> , 1996 , 82, 511-6	3.9	85
51	The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam. <i>Anesthesia and Analgesia</i> , 1996 , 82, 511-516	3.9	170
50	Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996 , 78, 117-22		19
49	The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996 , 79, 270-3		13
48	Itraconazole increases serum digoxin concentration. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996 , 79, 274-6		42

47	Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. <i>Epilepsia</i> , 1996 , 37, 253-7	6.4	120
46	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 7-13	6.1	200
45	The effect of ingestion time interval on the interaction between itraconazole and triazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 326-31	6.1	48
44	Diltiazem enhances the effects of triazolam by inhibiting its metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 369-75	6.1	58
43	Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 54-61	6.1	218
42	Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 319-23	3.8	58
41	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 465-470	3.8	52
40	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 465-70	3.8	21
39	Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 124-7	3.2	24
38	Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 270-272	3.8	75
37	Itraconazole interacts with felodipine. <i>Journal of the American Academy of Dermatology</i> , 1995 , 33, 134-5	4.5	37
36	Interaction between erythromycin and nitrazepam in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995 , 76, 255-8		10
35	Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 127-31	6.1	120
34	The effect of activated charcoal on the absorption and elimination of astemizole. <i>Human and Experimental Toxicology</i> , 1994 , 13, 502-5	3.4	11
33	Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 601-7	6.1	254
32	Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 481-5	6.1	356
31	Enhancement of drug absorption by antacids. An unrecognised drug interaction. <i>Clinical Pharmacokinetics</i> , 1994 , 27, 120-8	6.2	34
30	Dose of midazolam should be reduced during diltiazem and verapamil treatments. <i>British Journal of Clinical Pharmacology</i> , 1994 , 37, 221-5	3.8	138

29	Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. <i>Clinical Pharmacokinetics</i> , 1994 , 27, 1-5	6.2	64
28	Lack of interaction of erythromycin with temazepam. <i>Therapeutic Drug Monitoring</i> , 1994 , 16, 548-51	3.2	15
27	A potentially hazardous interaction between erythromycin and midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 53, 298-305	6.1	269
26	Failure of oral activated charcoal to accelerate the elimination of amiodarone and chloroquine. <i>Human and Experimental Toxicology</i> , 1992 , 11, 491-4	3.4	5
25	Reversible adsorption of nicotinic acid onto charcoal in vitro. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 917-9	3.9	8
24	Interference of dairy products with the absorption of ciprofloxacin. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 498-502	6.1	97
23	Effect of activated charcoal on the absorption of amiodarone. <i>Human and Experimental Toxicology</i> , 1991 , 10, 327-9	3.4	12
22	Enhancement of absorption and effect of glipizide by magnesium hydroxide. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 49, 39-43	6.1	15
21	Therapeutic Cyclosporine Monitoring. <i>Therapeutic Drug Monitoring</i> , 1990 , 12, 353-358	3.2	3
20	The clinical significance of food-drug interactions: a review. <i>Medical Journal of Australia</i> , 1989 , 150, 36-40		27
19	Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses. <i>Medical Toxicology</i> , 1988 , 3, 33-58		123
18	Can barbiturate anaesthesia cure infantile spasms?. <i>Brain and Development</i> , 1988 , 10, 300-4	2.2	2
17	Effect of total drug concentration on the free fraction in uremic sera. <i>Therapeutic Drug Monitoring</i> , 1986 , 8, 27-31	3.2	7
16	Bumetanide kinetics in renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 582-8	6.1	20
15	Effect of ethanol and pH on the adsorption of drugs to activated charcoal: studies in vitro and in man. <i>Acta Pharmacologica Et Toxicologica</i> , 1984 , 54, 1-7		39
14	Activated charcoal and syrup of ipecac in prevention of cimetidine and pindolol absorption in man after administration of metoclopramide as an antiemetic agent. <i>Journal of Toxicology: Clinical Toxicology</i> , 1984 , 22, 103-14		27
13	Adsorption of sulfonyleureas onto activated charcoal in vitro. <i>Journal of Pharmaceutical Sciences</i> , 1984 , 73, 253-6	3.9	23
12	Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. <i>Cephalalgia</i> , 1984 , 4, 253-63	6.1	52

11	Capacity of two forms of activated charcoal to adsorb nefopam in vitro and to reduce its toxicity in vivo. <i>Journal of Toxicology: Clinical Toxicology</i> , 1983 , 21, 333-42		8
10	Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 386-93	6.1	51
9	Pharmacokinetics of antiepileptic drugs. <i>Acta Neurologica Scandinavica</i> , 1983 , 97, 17-27	3.8	13
8	Clinical pharmacokinetics of oral activated charcoal in acute intoxications. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 465-89	6.2	134
7	Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1982 , 7, 269-76	2.7	12
6	Effect of phenytoin on serum lipoproteins in middle-aged men. <i>Journal of Cardiovascular Pharmacology</i> , 1981 , 3, 207-14	3.1	6
5	Pharmacokinetics of intravenously administered bumetanide in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1980 , 8, 219-28		27
4	Sotalol intoxication, two patients with concentration-effect relationships. <i>Acta Pharmacologica Et Toxicologica</i> , 1979 , 45, 52-7		19
3	Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. <i>Clinical Pharmacokinetics</i> , 1979 , 4, 91-103	6.2	53
2	Acute dapsone intoxication: a case with prolonged symptoms. <i>Clinical Toxicology</i> , 1979 , 14, 79-85		31
1	Severe poisoning in a child caused by a small dose of clonidine. <i>Clinical Toxicology</i> , 1979 , 14, 369-74		13